NVO vs VKTX
NVO: A leading global healthcare company with a heritage in diabetes, pioneering scientific breakthroughs to defeat serious chronic diseases through innovative medicines and expanded access. VKTX: Viking is developing VK2735, a novel dual GLP-1/GIP receptor agonist in Phase 3 trials for obesity and metabolic disorders, targeting a high-growth market currently dominated by single-agent GLP-1 therapies.
Side-by-side fundamentals
| Metric | NVO | VKTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $48.19 | $37.31 | |
| Market cap as of 2026-07-23 | $219.8B | $4.3B | |
| P/E as of 2026-07-23 | 11.78 | n/a | |
| PEG as of 2026-07-23 | 16.16 | -0.04 | VKTX lower |
| Net margin as of 2026-07-23 | +37.2% | n/a | |
| Gross margin as of 2026-07-23 | +81.8% | n/a | |
| Operating margin as of 2026-07-23 | +45.3% | n/a | |
| ROE as of 2026-07-23 | +66.4% | -71.3% | NVO higher |
| ROA as of 2026-07-23 | +23.3% | -65.3% | NVO higher |
| Debt / equity as of 2026-07-23 | 0.72 | 0.00 | VKTX lower |
| Revenue growth (YoY) as of 2026-07-23 | +8.1% | n/a | |
| Dividend yield as of 2026-07-23 | +3.7% | n/a | |
| Beta as of 2026-07-23 | 1.85 | 0.65 | |
| 1-year return as of 2026-07-22 close | -23.8% | +16.2% | VKTX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.